Related Experiment Video
Updated: Mar 22, 2026
08:43
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
Published on: January 31, 2020
7.4K
IL-6 blockade therapy for inflammatory diseases: current perspectives and future directions
1Department of Clinical Application of Biologics, Osaka University Graduate School of Medicine, Osaka University.
Summary
Interleukin-6 (IL-6) is crucial for homeostasis but drives inflammatory diseases when overproduced. Tocilizumab, an anti-IL-6 receptor antibody, effectively treats chronic inflammatory conditions and shows promise for severe inflammatory diseases.
Area of Science:
- Immunology
- Pharmacology
- Rheumatology
Background:
- Interleukin-6 (IL-6) is a pleiotropic cytokine essential for host defense and homeostasis.
- Dysregulated IL-6 production is implicated in the pathology of numerous inflammatory diseases.
- Targeting IL-6 emerged as a potential therapeutic strategy for inflammatory conditions.
Purpose of the Study:
- To evaluate the efficacy and safety of tocilizumab, a humanized anti-IL-6 receptor antibody.
- To explore the potential applications of IL-6 blockade in treating various inflammatory diseases.
Main Methods:
- Development of a humanized anti-IL-6 receptor antibody (tocilizumab).
- Clinical trials to assess efficacy and safety in patients with chronic inflammatory diseases.
- Ongoing studies investigating applications in immune-mediated and acute severe inflammatory diseases.
Main Results:
- Tocilizumab demonstrated efficacy and tolerable safety in clinical trials.
- Currently approved for treating rheumatoid arthritis, juvenile idiopathic arthritis, and Castleman's disease.
- Evidence suggests broad applicability for other chronic immune-mediated and acute severe inflammatory conditions.
Conclusions:
- Tocilizumab is an effective therapeutic agent for specific chronic inflammatory diseases.
- IL-6 blockade represents a significant advancement in managing inflammatory conditions.
- Further research is warranted to expand tocilizumab's therapeutic scope, including cytokine storm syndromes.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
655
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
655
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
722
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
722
01:24T Cell Types and Functions
3.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
606
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
606
01:29Inflammatory Bowel Disease IV: Pharmacological Management
910
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
910
01:27Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K